Volume | 95,022 |
|
|||||
News | - | ||||||
Day High | 3.02 | Low High |
|||||
Day Low | 2.87 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Gain Therapeutics Inc | GANX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
3.00 | 2.87 | 3.02 | 2.96 | 2.93 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
590 | 95,022 | US$ 2.93 | US$ 278,184 | - | 2.00 - 5.65 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
15:53:10 | 75 | US$ 3.07 | USD |
Gain Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
37.83M | 12.91M | - | 55k | -22.11M | -1.71 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Gain Therapeutics News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GANX Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.09 | 3.18 | 2.87 | 2.98 | 86,403 | -0.13 | -4.21% |
1 Month | 3.57 | 3.72 | 2.87 | 3.17 | 86,998 | -0.61 | -17.09% |
3 Months | 4.96 | 5.30 | 2.87 | 4.15 | 126,159 | -2.00 | -40.32% |
6 Months | 2.71 | 5.33 | 2.00 | 3.80 | 130,627 | 0.25 | 9.23% |
1 Year | 5.25 | 5.65 | 2.00 | 3.87 | 86,516 | -2.29 | -43.62% |
3 Years | 12.09 | 12.1144 | 2.00 | 5.06 | 80,518 | -9.13 | -75.52% |
5 Years | 11.22 | 17.93 | 2.00 | 5.62 | 83,255 | -8.26 | -73.62% |
Gain Therapeutics Description
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders and oncology. The company has filed four patent applications for novel small molecule drug candidates that are Structurally Targeted Allosteric Regulators (STARs). The company derives revenues from collaboration and licensing agreements. |